NOV 21, 2016 2:44 PM PST

Urine Test Shows Promise in Detection of Cervical Cancer

WRITTEN BY: Xuan Pham
For women at high risk for cervical cancer, Hopkins researchers say they have a new diagnostic test that’s both non-invasive and more accurate than current tests on the market.
 
In profiling the genetic mutations that underlie cervical cancer, the research team identified a four-gene combination that can serve as biomarkers for the disease. Furthermore, they say the test can be done with urine samples, instead of using tissues collected from Pap tests.
 
Currently, routine Pap tests are recommended every 3 years for women between 21 and 65 years old. The test takes a swab of the cervical tissue to look for cancer cells. Women who have an abnormal Pap results and also test positive for the human papillomavirus (HPV) are then asked to undergo a biopsy to rule out cervical cancer. However, this method of screening is invasive, costly, and may not be necessary in at least 50 percent of cases.
 
Using hundreds of cervical cells collected, the Hopkins team built a diagnostic platform that consisted of a 4-gene panel. Three genes (FKBP6, INTS1 and ZNF516) were identified because they are highly associated with cervical cancer. The fourth gene (HPV16-L1) is an HPV gene that becomes methylated with cancer progression. With this four-gene panel, the team reported a sensitivity of 90.9 percent and a specificity of 60.9 percent.
 

"When developing a new cancer screening test, we want something in the range of 90 to 95 percent sensitivity, which is competitive with the effectiveness of tests developed and now marketed in Europe," said Rafael Guerrero-Preston, professor at the Johns Hopkins School of Medicine, and the study’s first author.
 
The new test is reported to surpass the sensitivity of two commercial tests, which have sensitivity of only 64 percent. In addition, because the tests rely on DNA methylation, Pap smears are required.
 
"If further studies confirm these findings, we see a significant use of urine screening as a way to quickly and inexpensively determine if a biopsy is warranted, or if physicians can use a 'watch and wait' approach before intervening," said Guerrero-Preston.
 
"Our urine test would serve as a molecular triage," he says, "at times supplementing Pap test information. In developing countries that don't have the money, medical infrastructure or cultural approval for Pap test, our test could be used instead."
 
Additional sources: Hopkins press release via News Wise
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 04, 2020
Cardiology
Does Chronic Anxiety Affect Heart Health?
AUG 04, 2020
Does Chronic Anxiety Affect Heart Health?
Anxiety is something that is talked about far more often nowadays. In recent years, it has even been linked to a variety ...
AUG 20, 2020
Cardiology
A New Test to Discern Kawasaki Disease from Sepsis
AUG 20, 2020
A New Test to Discern Kawasaki Disease from Sepsis
Kawasaki disease is a rare cardiovascular disease affecting children under the age of five. If untreated, there is a cha ...
AUG 17, 2020
Clinical & Molecular DX
Smartphone Cameras Detect Signs of Diabetes
AUG 17, 2020
Smartphone Cameras Detect Signs of Diabetes
In the future, detecting the early signs of diabetes could be as simple as picking up your smartphone. A new study, rece ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
OCT 27, 2020
Clinical & Molecular DX
A Super Sensitive Alzheimer's Test Powered by Nanozymes
OCT 27, 2020
A Super Sensitive Alzheimer's Test Powered by Nanozymes
  Simple tasks are now uphill struggles, social situations aren’t fun, and the car keys are missing again. By ...
OCT 24, 2020
Clinical & Molecular DX
Software Flags Elevated Cerebral Palsy Risk in Premies
OCT 24, 2020
Software Flags Elevated Cerebral Palsy Risk in Premies
Diagnostic imaging scientists have developed a software tool for predicting the future onset of cerebral palsy in babies ...
Loading Comments...